Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)

NCT00238901 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00238901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00238901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2002
Completion date
Not reported
Enrollment
194 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

liver transplant